A clinical trial involving dulaglutide as a comparator was updated to completed status on September 18, 2026. The study, registered as NCT06779929 and titled "Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes," evaluated tirzepatide against dulaglutide or semaglutide. The trial focused on major cardiovascular events in participants with type 2 diabetes. No phase was specified in the available record for this update.
This update reflects a change in trial status only. The completion designation indicates that the study has concluded, but no results, outcomes, or efficacy data are included in this record. Readers should not infer benefit or harm for dulaglutide, tirzepatide, or semaglutide from this status change alone.
Dulaglutide remains an approved compound, and this trial update does not alter its regulatory status. Further details on the trial design, enrollment, and eventual findings would need to be sourced separately from the official registry listing.
For more background on dulaglutide, readers can consult the compound overview for additional context.